ArticlePatient preference and adherence2026
Determinants of Baseline Ophthalmic Screening and Its Association with Long-Term Treatment Persistence in Patients with Rheumatic Diseases Initiating Hydroxychloroquine: A Nationwide Cohort Study.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for various rheumatic diseases (RDs), but prolonged exposure carries a risk of irreversible retinal toxicity. Current guidelines recommend baseline ophthalmic screening to ensure safety and support treatment longevity. This study aimed to evaluate real-world adherence to baseline screening, identify its determinants, and assess its association with long-term HCQ treatment persistence. Patients and Methods: We conducted a nationwide retrospective cohort study using the South Korean Health Insurance Review and Assessment Service (HIRA) database. Adult patients with RDs who initiated HCQ between 2014 and 2018 and maintained therapy for ≥30 consecutive days were included. Baseline ophthalmic screening was defined as fundoscopy or optical coherence tomography (OCT) performed within 12 months of HCQ initiation, a pragmatic window reflecting real-world clinical practice. Determinants of screening were identified using multivariable logistic regression, and the association between screening and HCQ persistence was analyzed using Cox proportional hazards models. Results: Of the 19,876 patients included, only 32.5% underwent baseline screening. Independent predictors of higher screening rates included older age, female sex, treatment initiation at tertiary or general hospitals, a later initiation year, and a diagnosis of systemic lupus erythematosus, Sjögren's syndrome, or Behçet's disease. Conversely, concomitant use of conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids predicted lower rates. During follow-up, baseline ophthalmic screening was independently associated with significantly improved HCQ persistence (adjusted HR for discontinuation: 0.91; 95% CI: 0.88-0.94); this relationship held true specifically for patients undergoing baseline OCT (adjusted HR: 0.93; 95% CI: 0.88-0.98). Conclusion: These findings highlight the gap between guideline recommendations and real-world practice. The observed association between baseline ophthalmic screening, particularly utilizing OCT, and improved HCQ persistence suggests that such screening may potentially serve as an indicator of comprehensive clinical management within routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.